Cullgen Completes $50 Million Round for Protein Degradation Therapies

Cullgen, a San Diego-Shanghai small molecule company, completed a $50 million Series B financing to support its uSMITE™ platform for targeted protein degradation. The company develops first-in-class chemical entities that address unmet needs. Its platform is a ubiquitin-mediated, small molecule-induced target elimination technology (uSMITE™). Going beyond inhibition, the company's candidates are designed to eliminate previously undruggable enzymes and proteins. The company thinks novel E3 ligands provide the most promising pathway for eliminating targeted proteins. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.